Noncanonical NF-κB pathway is essential for the B cell activation and antibody production, which centralize the critical role of B cells in regulating the pathogenesis of systemic lupus erythematosus (SLE). We have previously demonstrated that Pellino1 (Peli1) negatively regulates noncanonical NF-κB activation and lupus autoimmunity. Here, we showed that poly IC is a potent inducer of Peli1 protein in mouse splenic B cells in dose-and time-dependent manners, and poly IC-induced Peli1 protein dramatically suppressed the activation of noncanonical NF-κB pathway. In addition, poly IC-pretreated B cells failed to induce lupus-like disease in BM12 CD4 + T cell-immunized mice.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple tissues and organs, which is attributed to the large amounts of autoantibodies in the circulation system [1] [2] [3] . The antibody-producing plasma cells are a type of terminally differentiated B cells, which centralize B cells as a critical regulator during SLE pathogenesis [4] . Indeed, many clinically applied treatments and clinical trials for SLE have been developed based on targeting B cells and its ability to produce antibodies [5] [6] [7] [8] . Although the essential role of B cells during SLE pathology is well known, the underlying molecular mechanism by which B cell activation and its antibody production are regulated is still poorly understood.
Previous studies have suggested that the noncanonical NF-κB signaling, which is activated through the B cell surface CD40, B cellactivating factor receptor, transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), etc., controls B cell activation and the ability of antibody production [9, 10] . Accordingly, the inactivation of NF-κB-inducing kinase (NIK), a master kinase for the activation of noncanonical NF-κB pathway, causes impaired ability of antibody production [11] . In addition, our previous studies have confirmed that NIK accumulation caused by the deletion of TBK1 or Otub7b dramatically promotes the activation of noncanonical NF-κB pathway, and the production of autoantibodies [12, 13] . Moreover, in vivo overexpression of BAFF leads to increased accumulation of NIK, hyper-activation of noncanonical NF-κB pathway and promoted the autoimmune symptoms of lupuslike disease [14] [15] [16] .
As an E3 ubiquitin ligase, the Pellino1 (Peli1) protein plays important roles in regulating the activation of innate and adaptive immune cells, which involves multiple receptor-induced signaling pathways such as toll-like receptor (TLR), interkeukin-1 receptor (IL-iR), and T cell receptor (TCR) [17] [18] [19] . Our recent study has identified Peli1 as an E3 ligase that directly mediates the K48-linked ubiquitination and degradation of NIK. The accumulation of NIK promotes the nuclear translocation of p52 and RelB and enhances the activation of noncanonical NF-κB in Peli1-deficient B cells. Therefore, Peli1 suppresses B cell activation and restrains the autoantibody production during lupus-like pathogenesis [20] . In addition, our study also suggested that overexpression of Peli1 dramatically inhibits the activation of noncanonical NF-κB signaling and alleviates lupus-like autoimmunity through promoting NIK ubiquitination and degradation [20] , implying a therapeutic role of upregulated Peli1 in lupus autoimmunity.
In the present study, we found that poly IC dramatically induced Peli1 expression in B cells, and poly IC-pretreated B cells exhibited suppressed activation of noncanonical NF-κB signaling, which is dependent on elevated Peli1 protein. Therefore, poly IC-pretreated B cells may have impaired ability to induce lupus-like autoimmunity in vivo.
Materials and Methods

Mice
Peli1-defcient (on a C57BL/6 background) mice, BM12 transgenic mice, and μMT mice were used as previously described [20] . All mice were maintained in a specific pathogen-free facility, and all animal experiment procedures were approved by the Institutional Biomedical Research Ethics Committee, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences (Shanghai, China).
Reagents
The anti-Peli1 (F-7, SC-271065), anti-p100/p52 (C-5, SC-7386), anti-RelB (C-19, SC-226), and anti-lamin B (C-20, SC-6216) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, USA). Antiactin antibody (AC-74, A2228) was purchased from Sigma (St Louis, USA). Anti-mouse CD40 antibody (553788) was from BD Biosciences (Franklin Lakes, USA). PE-cy7-conjugated anti-CD19 antibody (1D3, 25-0193-82), PE-conjugated anti-CD138 antibody (Syndecan-1, 142504), PB-conjugated anti-GL-7 antibody (48-5902-82), and APC-conjugated anti-Fas antibody (15A7, 17-0951-82) were purchased from eBioscience (San Diego, USA). Mouse CD45R (B220, 130-049-501) MicroBeads were purchased from Miltenyl Biotec (San Diego, USA).
Mouse immunization and antibody detection
To generate a lupus-like disease mouse model, 7.5 million of purified CD4 + BM12 T cells plus B220 + B cells that had been left untreated or stimulated with poly IC for 24 h were intraperitoneally injected into recipient μMT mice. Sera were collected at the indicated time points to examine anti-dsDNA, anti-ssDNA, and antihistone antibodies by ELISA using kits obtained from MyBioSource (San Diego, USA) [20] . The Hep-2 cells (Inova Diagnostics, San Diego, USA) were applied as a substrate to quantify the antinuclear antibodies in serum by using the following guidelines: 4+ = maximal fluorescence, brilliant yellow-green; 3+ = less brilliant yellow-green fluorescence; 2+ = definite but dull yellow-green fluorescence; and 1+ = very dim subdued fluorescence.
Four weeks after immunization, the kidneys were collected for IgG deposition analysis. Briefly, formalin-fixed frozen mouse kidney sections were stained with Alexa Fluor 488-conjugated goat antimouse IgG (Invitrogen, Carlsbad, USA). Antibody staining was detected using a fluorescent microscope (ZEISS, Jena, Germany).
Immunoblot assay
Splenic B220
+ B cells were sorted by using the mouse CD45R
MicroBeads. The purified B cells were left unstimulated or stimulated for appropriate time by anti-CD40. Total or subcellular extracts were prepared for immunoblot analysis with specific antibodies as described previously [20] .
Flow cytometry
Single-cell suspensions were stained with antibodies against different cell surface markers, followed by incubation for 25 min on ice, and then the cells were resuspended in PBS with 2% FBS for flow cytometry analysis. For the gating strategy, FSC/SSC is initially applied, and then antibodies with specific fluorochrome were used to make the subsequent gates. All the samples in the same experiments and comparisons were gated under the same parameters.
Statistical analysis
Except where otherwise indicated, all the presented data are representative results of at least three independent repeats. Data are presented as the mean ± SEM, and the P-values were determined by two-tailed Student's t-tests. P-value <0.05 is considered statistically significant.
Results
Poly IC is a potent inducer of Peli1 protein in B cells
Published studies have suggested that TBK1 activation through Trifdependent TLR-signaling pathway is critical for the induction of Peli1 protein in innate immune cells [21] . To examine whether Peli1 is inducible in B cells, mouse primary splenic B cells were isolated, and then stimulated with Poly IC, a specific ligand for TLR3, to activate TBK1 in Trif-dependent pathway. As expected, poly IC stimulation activated TBK1 as characterized by induced phosphorylation of TBK1 in a time-dependent manner (Fig. 1A) . Accordingly, poly IC dramatically induced Peli1 protein expression in mouse splenic B cells (Fig. 1B,C) . In addition, the Peli1 protein levels were further elevated along with the increased concentration or stimulation time of poly IC as compared with nonstimulated cells (Fig. 1B,C) , suggesting that poly IC induces Peli1 protein expression in B cells in dose-and time-dependent manners.
Poly IC pretreatment inhibited noncanonical NF-κB pathway dependent on Peli1
Since we recently demonstrated that overexpression of Peli1 could inhibit the activation of noncanonical NF-κB-signaling pathway [20] , we speculated that poly IC-induced Peli1 protein expression may also have suppressive effect on this pathway. Therefore, splenic B cells were pretreated with poly IC for 24 h to induce the expression of Peli1 protein, and then cells were stimulated with anti-CD40, a commonly used noncanonical NF-κB inducer. As shown in Fig. 2A , poly IC pretreatment dramatically impaired the activation of noncanonical NF-κB signaling, as characterized by suppressed translocation of transcriptional factors RelB and p52 into the nuclear, along with increased expression of Peli1 protein in wildtype mouse splenic B cells. In contrast, poly IC pretreatment could not affect the activation of noncanonical NF-κB in Peli1-deficient B cells (Fig. 2B) . These data collectively suggested that poly IC pretreatment indeed suppresses noncanonical NF-κB activation, which is dependent on its induction of Peli1 protein in B cells.
Poly IC-pretreated B cells suppressed the induction of lupus-like autoimmunity
To exlpore the in vivo function of poly IC-pretreated B cells in regulating SLE pathogenesis, we transferred equal amount of C57BL/6 mice B cells that had been left untreated or pretreated with poly IC for 24 h, together with CD4 + T cells isolated from BM12 mice, into the B cell-deficient μMT mice to induce lupus-like disease (Fig. 3A) .
In this model, the recipient antigen-presenting cells will activate the donor BM12 CD4 + T cells, which will differentiate into T follicular cells (Tfhs) to initiate the germinal center reaction and promote the 
GL-7
+ GC B cells in the spleen (Fig. 4A,B) .
Taken together, these results revealed that poly IC-pretreated B cells loss the ability to induce lupus-like autoimmunity.
Poly IC pretreatment impaired autoantibody secretion through induction of Peli1
Since the hallmark of lupus-like disease is the uncontrolled production of autoantibodies [1] [2] [3] , to further confirm the inhibitory effect of poly IC-pretreated B cells on the induction of lupus-like autoimmunity, we examined the secretion of autoantibodies in the sera of immunized recipient μMT mice. Expectedly, the production of serum antinuclear antibody was significantly reduced in the recipient mice transferred with poly IC-pretreated B cells plus BM12 CD4 + T cells, as compared with that in the recipient mice transferred with untreated B cells (Fig. 5A,B) . Consistently, the sera levels of IgG and IgM against dsDNA, ssDNA and histone were also significantly decreased in the recipient mice transferred with poly IC-pretreated B cells plus BM12 CD4 + T cells (Fig. 5C,D) . Collectively, our data suggested that poly IC-pretreated B cells are inefficient to induce antibody production, thus inhibiting the development of lupus-like disease.
To further explore whether the inhibitory effect of poly ICpretreated B cells on the induction of lupus-like autoimmunity is due to the induction of Peli1, we transferred μMT mice with equal amount of Peli1-deficient B cells that had been left untreated (NT) or pretreated with poly IC, together with CD4 + T cells isolated from BM12 mice, to induce lupus-like disease. It was found that there was no obvious difference between the two groups of recipient μMT mice as characterized by comparable levels of antinuclear antibodies and autoantibodies in the serum (Fig. 6A-D) . These data collectively confirmed that the inhibitory effect of poly IC-pretreated B cells on the induction of lupus-like autoimmunity is depended on its induction of Peli1 protein in B cells.
Discussion
Peli was initially discovered as a Drosophila innate immune regulator which was identified as a Pelle-interacting protein that mediates the activation of NF-κB. Peli is evolutionarily conserved, which shares more than 50% identity of amino acid sequences between different species [22] [23] [24] . The mammalian Peli family contains three members, Peli1, Peli2, and Peli3, which share more than 80% sequence homology, suggesting that there may be functional compensation among these three Peli members [25, 26] . Recently, we demonstrated that Peli1 negatively regulates B cells-mediated lupuslike autoimmunity, and that overexpression of Peli1 in B cells dramatically alleviates lupus-like disease, suggesting a potential therapeutic function of Peli1 protein for lupus-like disease [20] . Moreover, we also provided clinical evidence that Peli1 is negatively correlated with SLE disease activity because lower expression of Peli1 suggests more severe disease activity and autoantibody production in SLE patients [20] . In the present study, we identified poly IC as a potent inducer of Peli1 protein in B cells. Accordingly, poly ICpretreated B cells are inefficient to induce the lupus-like disease, which is consistent with our previous report [20] . We have previously elucidated the critical role of Peli1 in regulating Trif-dependent TLR signaling in innate immune cells and mouse embryonic fibroblast [18] , as well as in modulating the TCR signaling for T cell activation and proliferation [19] . In B cells, we identified Peli1 as a direct E3 ubiquitin ligase of NIK, which negatively regulated the activation of noncanonical NF-κB signaling. On the contrary, overexpression of Peli1 in B cells dramatically inhibited noncanonical NF-κB activation [20] . Since noncanonical NF-κB pathway is essential for the B cell activation and antibody production during SLE pathogenesis, therapeutic strategies that restrain the activation of this pathway may exhibit beneficial effect for SLE treatment. Indeed, we provided genetic evidence that poly ICinduced Peli1 is required for the suppression of noncanonical NF-κB signaling because poly IC pretreatment failed to inhibit noncanonical NF-κB activation in Peli1-deficient B cells. Interestingly, the negative role of Peli1 in regulating noncanonical NF-κB pathway is not only restricted in B cells, since Peli1 deficiency also enhanced the activation of this pathway in mouse embryonic fibroblast upon anti-LTβR stimulation and promoted the mucosal immunity [20] . Therefore, poly IC-induced Peli1 may also have therapeutic effect for mucosal-related diseases.
Poly IC is a specific ligand for TLR3, which activates TBK in Trif-dependent TLR-signaling pathway to mediate the transcriptional activation of genes encoding type I interferons and proinflammatory cytokines [27, 28] . Therefore, poly IC is now widely used as a clinically approved vaccine adjuvant for cancer immunotherapy and antiviral immunity [29] [30] [31] . Published studies have suggested that TBK1 in Trif-dependent TLR-signaling pathway is critical for the induction of Peli1 expression in innate immune cells as macrophages [22] . Here, we identified that poly IC also functions as a potent inducer of Peli1 protein expression in B cells in dose-and time-dependent manners. More interestingly, poly ICpretreated B cells have impaired ability to produce autoantibodies and fail to induce the lupus-like autoimmunity. Therefore, we demonstrated a novel function of poly IC that negatively regulates B cell activation and further restrains lupus-like autoimmunity. We have previously identified TBK1 as a negative regulator of NIK, which suppresses the activation of noncanonical NF-κB pathway [12] . However, poly IC-pretreated Peli1-deficient B cells are inefficient to suppress lupus-like autoimmunity, suggesting that the inhibitory effect of poly IC is dependent of the induction of Peli1 protein but is dispensable for its activation of TBK1. The reason for this phenomenon may be that poly IC-activated phosphorylation of TBK1 is only a transient effect, whereas the induced Peli1 protein lasts much longer to function as a potent suppressor of noncanonical NF-κB pathway. Therefore, we propose that the kinase TBK1
and poly IC-induced Peli1 may function separately to modulate the activation of noncanonical NF-κB pathway. In summary, our study established poly IC as a potent inducer of B cell Peli1 protein, which suppresses the activation of noncanonical NF-κB pathway and further inhibits the induction of lupus-like disease. Given the role of Peli1 in restraining lupus-like autoimmunity, poly IC-induced Peli1 may have therapeutic implication for SLE treatment. 
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